(Q36863534)

16 August 2017

1 reference

title

Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade (English)

1 reference

16 August 2017

1 reference

Weir MR

1

1 reference

16 August 2017

language of work or name

1 reference

28 June 2007

1 reference

Journal of Human Hypertension

16 August 2017

published in

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

10

1 reference

16 August 2017

page(s)

770-779

1 reference

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Assessment of global risk: a foundation for a new, better definition of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of AT1 receptor blockade on endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Renin-angiotensin system and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Nitric oxide, angiotensin II, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effects of antihypertensive drugs on endothelial dysfunction: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Different effect of antihypertensive drugs on conduit artery endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Valsartan improves fibrinolytic balance in atherosclerotic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin II AT(1) receptor antagonists and platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

A rationale for combination therapy in risk factor management: a mechanistic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Atheroprotective Effects of Long-Acting Dihydropyridine-Type Calcium Channel Blockers: Evidence from Clinical Trials and Basic Scientific Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Clinical importance of microalbuminuria in diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

Angiotensin II Type 1 Receptor Blockade Improves Hyperglycemia-Induced Endothelial Dysfunction and Reduces Proinflammatory Cytokine Release From Leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002254

21 January 2018

Identifiers

DOI

10.1038/SJ.JHH.1002254

1 reference

16 August 2017

1 reference